CanSino Biologics, Inc. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

3SBio, Inc.

Alphamab Oncology

Frontage Holdings Corp.

Sirnaomics Ltd.

Beijing Lüzhu Biotechnology Co., Ltd.

Laekna, Inc.

Ascentage Pharma Group International Co., Ltd.

AIM Vaccine Co., Ltd.

Zai Lab Ltd.

CanSino Biologics, Inc.

Genscript Biotech Corp.

Why is CanSino Biologics, Inc. ?

Weak Long Term Fundamental Strength with a -1.44% CAGR growth in Operating Profits over the last 5 years

Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -60.98

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 18.32%, its profits have risen by 81.1%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is CanSino Biologics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

CanSino Biologics, Inc.

18.32%

1.29

57.86%

Hang Seng Hong Kong

27.36%

1.06

25.88%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

174.57%

EBIT Growth (5y)

-1.44%

EBIT to Interest (avg)

-60.98

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.23

Sales to Capital Employed (avg)

0.09

Tax Ratio

1.16%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

25.84%

ROE (avg)

4.54%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.21

EV to EBIT

-15.78

EV to EBITDA

-42.01

EV to Capital Employed

1.29

EV to Sales

5.02

PEG Ratio

Dividend Yield

ROCE (Latest)

-8.17%

ROE (Latest)

-3.37%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Not enough Data to analyse Financial Trend

Here's what is working for CanSino Biologics, Inc.

Net Sales

At HKD 585.22 MM has Grown at 67.14%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very positive

Net Sales (HKD MM)

Net Profit

Highest at HKD -164.6 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (HKD MM)

Net Sales

Highest at HKD 585.22 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (HKD MM)

Operating Profit Margin

Highest at -18.91 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at HKD -162.35 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (HKD MM)

Pre-Tax Profit

At HKD -162.35 MM has Grown at 78.43%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (HKD MM)

Net Profit

At HKD -164.6 MM has Grown at 76.24%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (HKD MM)

EPS

Highest at HKD -0.67

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (HKD)

Raw Material Cost

Fallen by -145.93% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for CanSino Biologics, Inc.

Debt-Equity Ratio

Highest at -24.28 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Cash and Eqv

Lowest at HKD 3,411.48 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Inventory Turnover Ratio

Lowest at 1.03%

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio